NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing ...

With this growing body of evidence, Artelo continues to expand its leadership in the FABP inhibitor space. The Company maintains a portfolio of selective, dual, and pan inhibitors targeting FABP3, ...

Data Demonstrating Unique Benefits of Sotagliflozin in Diverse Patient Populations will be Presented at the Hypertrophic Cardiomyopathy Society and American Heart Association’s Sessions 2025 in New ...

With new and elevated leaders, InStride is poised to scale its care model while maintaining its differentiated specialty care. BOSTON, Nov. 04, 2025 (GLOBE NEWSWIRE) -- InStride H ...

Mr. Bagai will share an update on RenovoRx’s commercialization progress, driven by strong clinical need and market demand for RenovoCath as a standalone targeted drug-delivery product among both new ...

BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today announced ...

The presentations will premiere at the time listed above and can be accessible by visiting the Presentation & Events section on the “Investors” page of Aligos’ website at www.aligos.com. A replay of ...